Advaxis, Inc. (NASDAQ:ADXS) shares gapped up prior to trading on Wednesday . The stock had previously closed at $1.00, but opened at $1.08. Advaxis shares last traded at $1.02, with a volume of 5,708,534 shares trading hands.

Separately, Zacks Investment Research downgraded Advaxis from a “buy” rating to a “hold” rating in a report on Wednesday, October 30th.

The firm has a market capitalization of $65.64 million, a price-to-earnings ratio of -25.18 and a beta of 4.13. The company has a fifty day moving average price of $1.00 and a two-hundred day moving average price of $0.56.

Advaxis (NASDAQ:ADXS) last posted its quarterly earnings data on Friday, December 20th. The biotechnology company reported ($0.15) earnings per share for the quarter. Advaxis had a negative net margin of 79.31% and a negative return on equity of 40.98%.

Several hedge funds have recently bought and sold shares of ADXS. Raymond James Financial Services Advisors Inc. boosted its holdings in shares of Advaxis by 206.3% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 50,000 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 33,675 shares during the period. Sabby Management LLC boosted its holdings in shares of Advaxis by 3,547.9% in the third quarter. Sabby Management LLC now owns 1,521,982 shares of the biotechnology company’s stock valued at $403,000 after acquiring an additional 1,480,260 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Advaxis by 71.1% in the second quarter. Vanguard Group Inc. now owns 230,106 shares of the biotechnology company’s stock valued at $481,000 after acquiring an additional 95,607 shares during the period. Finally, Renaissance Technologies LLC boosted its holdings in shares of Advaxis by 90.9% in the fourth quarter. Renaissance Technologies LLC now owns 3,780,083 shares of the biotechnology company’s stock valued at $3,242,000 after acquiring an additional 1,800,297 shares during the period. 30.56% of the stock is owned by institutional investors and hedge funds.

Advaxis Company Profile (NASDAQ:ADXS)

Advaxis, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer.

Featured Story: Treasury Bonds

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.